Drug establishment licences and COVID-19

All Canadian drug establishments must have a drug establishment licence to fabricate, package/label, distribute, import, wholesale or test a drug as required under Part C, Division 1A of the Food and Drug Regulations.

Data and Resources

Additional Info

Field Value
Source
Version
Author
Author Email
Maintainer
Maintainer Email
Data Level
Agreement Required
Purpose Constraints
Redistribution Allowed
AI Training Allowed
Data Steward
Title (French) Les licences d’établissement de produits pharmaceutiques et la COVID-19
Update Frequency as_needed
Geographic Scope []
Criticality Level []
Sensitivity Level unrestricted
Language
Contact Person
Contact Email
Data Dictionary
Open Canada Date Published 2020-08-08 00:00:00
Open Canada Date Modified
Open Canada Subject ["health_and_safety"]
Open Canada Keywords {"fr": ["Pandémie de COVID-19", "licences d’établissement de produits pharmaceutiques", "Partie C", "Division 1A du Règlement sur les aliments et drogues"], "en": ["COVID-19 pandemic", "Drug establishment licences", "Part C", "Division 1A of the Food and Drug Regulations."]}
Open Canada Collection publication
Principal Organization
Reference Data
Official Source